Sign in

You're signed outSign in or to get full access.

STRYKER (SYK)

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for STRYKER.

Q3 2025

→

Q2 2025

→

Q1 2025

→

Q4 2024

→

Executives

Executive leadership at STRYKER.

Kevin Lobo

Detailed

Chief Executive Officer

CEO

Andrew Pierce

Detailed

Group President, MedSurg and Neurotechnology

Preston Wells

Detailed

Chief Financial Officer

Spencer Stiles

Detailed

Group President, Orthopaedics

Viju Menon

Detailed

Group President, Global Quality and Operations

Board Members

Board of directors at STRYKER.

Andrew Silvernail

Detailed

Director

Emmanuel Maceda

Detailed

Director

Giovanni Caforio

Detailed

Director

Lisa Skeete Tatum

Detailed

Director

Mary Brainerd

Detailed

Director

Rachel Ruggeri

Detailed

Director

Rajeev Suri

Detailed

Director

Ronda Stryker

Detailed

Director

Sherilyn McCoy

Detailed

Lead Independent Director

Analyst Coverage

Research analysts who have asked questions during STRYKER earnings calls.

Danielle Antalffy

UBS Group AG

6 questions for SYK

Also covers: ABT, ATRC, BAX +15 more

Travis Steed

Bank of America

6 questions for SYK

Also covers: ABT, AXNX, BAX +19 more

Vijay Kumar

Evercore ISI

6 questions for SYK

Also covers: A, ABT, AVTR +21 more

Joanne Wuensch

Citigroup Inc.

5 questions for SYK

Also covers: ABT, BAX, BDX +18 more

Michael Matson

Needham & Company

5 questions for SYK

Also covers: AORT, ATRC, CNMD +22 more

Ryan Zimmerman

BTIG

5 questions for SYK

Also covers: ALC, GEHC, GKOS +23 more

Richard Newitter

Truist Securities

4 questions for SYK

Also covers: AXNX, DXCM, GKOS +18 more

Robert Marcus

JPMorgan Chase & Co.

4 questions for SYK

Also covers: ABT, BAX, BDX +21 more

Caitlin Cronin

Canaccord Genuity

3 questions for SYK

Also covers: ATEC, AXGN, BVS +10 more

David Roman

Goldman Sachs Group Inc.

3 questions for SYK

Also covers: ABT, BAX, BDX +18 more

Jenny Rabinowitz

Goldman Sachs Group Inc.

3 questions for SYK

Also covers: SOLV

Larry Biegelsen

Wells Fargo & Company

3 questions for SYK

Also covers: ABT, ALC, AXNX +24 more

Matthew Miksic

Barclays PLC

3 questions for SYK

Also covers: ABT, ATEC, BAX +15 more

Matthew O'Brien

Piper Sandler & Co.

3 questions for SYK

Also covers: APYX, ATEC, ATRC +18 more

Matt Miksic

Barclays Investment Bank

3 questions for SYK

Also covers: ABT, ATEC, BAX +14 more

Pito Chickering

Deutsche Bank

3 questions for SYK

Also covers: ACHC, AHCO, AVAH +18 more

Shagun Singh Chadha

RBC Capital Markets

3 questions for SYK

Also covers: AXNX, DXCM, GMED +11 more

Chris Pasquale

Nephron Research LLC

2 questions for SYK

Also covers: ALC, AXGN, BSX +7 more

Eric Anderson

TD Cowen

2 questions for SYK

Also covers: ATEC, CERS, RBOT +2 more

Kendall

Royal Bank of Canada

2 questions for SYK

Larry Beagleson

Wells Fargo

2 questions for SYK

Also covers: DXCM

Matthew Taylor

Jefferies

2 questions for SYK

Also covers: ALUR, BDX, CQP +18 more

Philip Chickering

Deutsche Bank AG

2 questions for SYK

Robbie Marcus

JPMorgan Chase & Co.

2 questions for SYK

Also covers: ABT, BAX, BDX +9 more

Samantha Kurtz

Piper Sandler Companies

2 questions for SYK

Also covers: PEN

Steven Lichtman

Oppenheimer & Co. Inc.

2 questions for SYK

Also covers: ALC, ANGO, COO +12 more

Christopher Pasquale

Nephron Research

1 question for SYK

Also covers: ALC, AXGN, BSX +12 more

Jason Wittes

Roth Capital Partners, LLC

1 question for SYK

Also covers: ALUR, ARAY, ATEC +13 more

Jeffrey Johnson

Robert W. Baird & Co. Inc.

1 question for SYK

Also covers: ALC, ALGN, BBNX +11 more

Joshua Jennings

TD Cowen

1 question for SYK

Also covers: ABT, ALUR, ATEC +20 more

Kaitlin Cronin

Canaccord Genuity Group Inc.

1 question for SYK

Lawrence Biegelsen

Wells Fargo

1 question for SYK

Also covers: ABT, ALC, BAX +16 more

Matthew Aspro

Jefferies

1 question for SYK

Matt O'Brien

Piper Sandler Companies

1 question for SYK

Also covers: BBNX, BSX, DXCM +6 more

Michael Polark

Wolfe Research

1 question for SYK

Also covers: BSX, DXCM, EMBC +10 more

Mike Matson

Needham & Company, LLC

1 question for SYK

Also covers: CNMD, ENOV, ESTA +16 more

Patrick Wood

Morgan Stanley

1 question for SYK

Also covers: ALC, BDX, BLCO +17 more

Latest news

Recent press releases and 8-K filings for SYK.

Stryker outlines growth strategy at Investor Day 2025
SYK
M&A
Guidance Update
Product Launch
  • Continued fast growth driven by prioritized M&A in high-growth areas (e.g., healthcare IT with Vocera, Care.ai and Inari) to raise the weighted average market growth rate
  • Decentralized operating model with specialized business units (GM-led sales, marketing, R&D) complemented by Customer Solutions for pricing, contracting and ASC programs to deliver comprehensive offerings
  • Financial commitment to double-digit EPS growth in 2026–2028, with ~70% of capital allocated to acquisitions, moderate dividend increases and no share buybacks planned
  • Emphasis on innovation across power brands—including robotics, 3D-printed implants, the virtual nurse (Care.ai) and the newly FDA-cleared MAKO RPS handheld robotic system for joint replacement’s standard-of-care segment
Nov 13, 2025, 7:30 PM
Transcript
Stryker Reports 10% Q3 Sales Growth, Raises 2025 Guidance
SYK
Earnings
Guidance Update
Product Launch
  • Third-quarter net sales rose 10.3% to $6.1 billion, and adjusted EPS increased 11.1% to $3.19, outperforming expectations.
  • Full-year outlook raised to 9.8%–10.2% organic net sales growth and $13.50–$13.60 adjusted EPS.
  • Operating income margin was 18.7% (adjusted 25.6%), while free cash flow margin declined to 22.3% from 23.7%, indicating some margin pressure.
  • Innovation pipeline advanced with the FDA-cleared Incompass total ankle system launch and a neurovascular robotics partnership with Siemens Healthineers.
Oct 31, 2025, 6:04 AM
WSJ
Stryker reports Q3 2025 results
SYK
Earnings
Guidance Update
M&A
  • Delivered 9.5% organic sales growth and $3.19 adjusted EPS (+11.1% y/y) in Q3 2025
  • Raised full-year 2025 guidance to 9.8%–10.2% organic sales growth and $13.50–$13.60 EPS
  • Achieved 65% adjusted gross margin (+50 bps) and 25.6% adjusted operating margin (+90 bps) despite ~$200 million tariff impact
  • Completed tuck-in acquisitions of Guard Medical NP Seal and Advanced Medical Balloons and advanced Inari integration with $590 million pro forma sales in 10 months
Oct 30, 2025, 8:30 PM
Transcript
Stryker reports Q3 2025 results and raises full-year outlook
SYK
Earnings
Guidance Update
M&A
  • Organic sales grew 9.5% year-over-year and adjusted EPS was $3.19, up 11.1%, driven by strong demand across businesses.
  • Adjusted gross margin reached 65% (up 50 bp) and adjusted operating margin was 25.6% (up 90 bp); year-to-date operating cash flow was $2.9 billion.
  • MedSurg & Neurotechnology sales rose 8.4% (U.S. +9.4%, International +5.1%) and Orthopaedics grew 11.4% (U.S. +12.9%, International +7.8%).
  • Completed small tuck-in acquisitions of Guard Medical’s NP Seal and Advanced Medical Balloons and emphasized continued M&A activity.
  • Raised full-year 2025 guidance to 9.8%–10.2% organic net sales growth and $13.50–$13.60 adjusted EPS.
Oct 30, 2025, 8:30 PM
Transcript
Stryker reports Q3 2025 results
SYK
Earnings
Guidance Update
M&A
  • Delivered 9.5% organic sales growth and 11.1% adjusted EPS growth to $3.19 in Q3 2025.
  • Raised full-year 2025 outlook to 9.8–10.2% organic net sales growth and $13.50–$13.60 adjusted EPS.
  • Achieved 11.4% organic growth in Orthopaedics (U.S. 12.9%, international 7.8%) and 8.4% in MedSurg & Neurotechnology (U.S. 9.4%, international 5.1%).
  • Expanded margins with a 65% adjusted gross margin (+50 bps) and 25.6% operating margin (+90 bps), partly offset by an estimated $200 million tariff headwind for 2025.
  • Completed tuck-in acquisitions of NP Seal and Advanced Medical Balloons; recorded best-ever MEKO installations; launched Lifepak 35 in Europe; Inari integration drove double-digit pro forma growth and ~$590 million in 10-month sales.
Oct 30, 2025, 8:30 PM
Transcript
Stryker reports Q3 2025 operating results
SYK
Earnings
Guidance Update
  • Stryker reported Q3 net sales of $6.1 billion, up 10.3% year-over-year; organic net sales grew 9.5%.
  • Reported operating margin was 18.7%, while adjusted operating margin rose 90 bps to 25.6%.
  • Reported EPS was $2.22 (+2.8%), and adjusted EPS was $3.19 (+11.1%).
  • Raised full-year 2025 guidance to 9.8%–10.2% organic net sales growth and $13.50–$13.60 adjusted EPS.
  • MedSurg & Neurotechnology sales climbed 14.4% to $3.8 billion, and Orthopaedics sales increased 3.9% to $2.3 billion.
Oct 30, 2025, 8:15 PM
8-K
Stryker reports Q3 2025 operating results
SYK
Earnings
Guidance Update
Revenue Acceleration/Inflection
  • Net sales rose 10.3% year-over-year to $6.1 billion, driven by 9.5% organic growth.
  • Adjusted operating margin expanded 90 bps to 25.6%, while reported margin was 18.7%.
  • Adjusted EPS increased 11.1% to $3.19; reported EPS was $2.22, up 2.8%.
  • Organic net sales by segment: MedSurg & Neurotech $3.8 billion (+8.4% organic), Orthopaedics $2.3 billion (+11.4% organic).
  • Raised full-year 2025 guidance for organic net sales growth to 9.8–10.2% and adjusted EPS to $13.50–$13.60.
Oct 30, 2025, 8:05 PM
Press Release
Stryker launches next-gen InThrill Thrombectomy System
SYK
Product Launch
M&A
  • Stryker’s Inari division launched the next-generation InThrill Thrombectomy System on July 29, 2025, marking the first purpose-built small vessel and arteriovenous access thrombectomy device.
  • The 8 French over-the-wire system features increased radial force, offset single open mouth, internal struts, and a redesigned backend to optimize clot removal and user ergonomics.
  • The first commercial case occurred on May 19, 2025 at UPMC, with physicians reporting more effective and consistent thrombectomies.
  • Stryker completed its acquisition of Inari Medical on February 19, 2025, integrating Inari’s vascular device expertise into its portfolio.
Jul 29, 2025, 1:07 PM
Press Release
Stryker gains FDA clearance for Incompass Total Ankle System
SYK
Product Launch
M&A
  • Stryker received FDA 510(k) clearance for its Incompass Total Ankle System, integrating Inbone and Infinity platform technologies to enhance long-term fixation and procedural efficiency.
  • The implant was developed using the SOMA platform and Prophecy Surgical Planning System, leveraging data from 85,000 CT scans and 100,000 clinical cases for personalized patient anatomy alignment.
  • In Q1 2025, Stryker delivered 10.1% organic sales growth, an adjusted operating margin of 22.9% (up 100 bps year-over-year), and a 121.01% five-year total shareholder return.
  • Earlier in 2025, Stryker expanded into the venous thromboembolism market by acquiring Inari Medical for nearly $4.9 billion.
Jun 25, 2025, 1:45 PM
Morningstar
Stryker Outlines Growth Initiatives and Pricing Strategy in Special Call
SYK
M&A
Revenue Acceleration/Inflection
Product Launch
  • Differentiated commercial model drives sustained double-digit revenue growth supported by both internal innovation and proactive M&A, including the recent divestiture of the Spine business and acquisition of Inari.
  • Pricing strategies have been refined to mitigate tariff impacts and improve product margin performance, contributing to more positive pricing outcomes across segments.
  • The company reports a robust capital order book with a strong pipeline in its Orthopaedics and MedSurg businesses, signaling a healthy outlook for future growth.
May 13, 2025, 8:41 PM
Transcript

Earnings Transcripts

Quarterly earnings call transcripts for STRYKER.

Q3 2025

Oct 30, 2025

→

Q2 2025

Jul 31, 2025

→

Q1 2025

May 1, 2025

→
View All Transcripts
Fintool

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Kevin Lobo say about margins?What are STRYKER's strategic priorities?How is STRYKER positioned vs competitors?How did STRYKER do last quarter?